设计多反应和激活微凝,以实现按需释放药物
Priyanshi Agnihotri1, Divya Dheer1,2, Anvi Sangwan3
1Chemical Biology Unit, Institute of Nano Science and Technology, Knowledge City, Sector 81, Mohali 140306, Punjab, India. apal@inst.ac.in.
Nanoscale
|September 30, 2024
概括
研究人员开发了能够控制药物输送的新型刺激响应微凝. 这些生物相容的微凝对温度,pH值和光线做出反应,使得可以根据需要释放西普洛素 (Cf).
科学领域:
- 材料科学 材料科学 材料科学
- 聚合物化学 聚合物化学
- 生物医学工程 生物医学工程
背景情况:
- 多功能合体微凝对于先进材料至关重要.
- 刺激反应和生物相容的微凝是功能网络的关键.
- 含有亚的微凝具有对光敏感的特性.
研究的目的:
- 设计和合成新的刺激反应微凝.
- 为了研究微凝对温度,pH值和光线的反应.
- 评估这些微凝在控制药物输送方面的潜力.
主要方法:
- 用HEMA-Az和EGDMA交叉连接剂对DEGMA和MAA单体的共聚化.
- 使用光谱,显微镜和光散射技术进行表征.
- 评估药物 (西普罗夫洛克萨) 加载和释放动力学.
主要成果:
- 合成的微凝 (M0,M1,M2) 与温度,pH值和紫外线照射有可逆的膨胀/脱水.
- 微凝M2在pH值5.5时显示了增强的光激活和液体送.
- 在pH 5和37°C时,从微凝M2中观察到普洛素的光学反应释放.
结论:
- 开发的微凝表现出可调节的刺激反应行为.
- 微凝M2是光控制药物递送系统的有希望的候选者.
- 这些发现突出了按需治疗应用的潜力.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...


